The spread has widened to 8% due to regulatory approval concerns. Regulatory approval should be forthcoming as the transaction involves Chinese entities acquiring a Chinese-focused company.
What is covered in the Full Insight:
Transaction Delay Explanation
Closing Conditions Status
Chinese Regulatory Approvals Introduction
NDRC, MOFCOM and SAFE Procedures
Reasons why regulatory approvals should be forthcoming
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.